NICE 2018 will provide unparalleled opportunities for sponsorship which will allow you to meet key business and marketing objectives to position yourself amongst the industry’s key decision makers.

Choose from a range of options providing face-to-face lead generation and customer communication opportunities, as well as platforms to boost brand awareness and thought leadership credentials.

Options available include:

  • Networking reception - Shared Learning Awards
  • Fringe sessions
  • Exhibition packages
  • Advertising opportunities

To find out more about the opportunities available and a breakdown of attendees, please contact us and request our media pack.

For sponsorship opportunities, please contact our team Customer.Service@dodsgroup.com | +44 (0)20 7593 5500.


British Heart Foundation

We are the nation's heart charity and the largest independent funder of cardiovascular research. Coronary heart disease is the UK's single biggest killer but we are leading the fight against it. Our pioneering research has been key in developing our best practice programmes that have helped transform the care of people living with heart and circulatory conditions.

Website: www.bhf.org.uk

Twitter: @TheBHF




Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Inflectra® / Remsima® (CT-P13, biosimilar infliximab) which is the world’s first monoclonal antibody (mAb) biosimilar, received FDA and EMA approval, respectively. Truxima® (CT-P10, biosimilar rituximab) and Herzuma® (CT-P6, biosimilar trastuzumab) also received EMA approval. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries.



Evidera, PPD’s peri- and post-approval business unit, is a leading provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products. We help companies generate the evidence needed to optimize the market access and commercial potential of their products. We provide integrated and tailored scientific expertise and global operational capabilities. Our offerings include interventional studies, real-world observational research, data analytics, patient-centered outcomes studies, epidemiological studies, modeling and simulation, meta-analysis, literature reviews, market access consulting and communications, and medical writing. Our staff have contributed to hundreds of payer/regulatory submissions, and have published over 2,200 peer-reviewed articles.

LumiraDx Care Solutions

Twenty years ago, we began helping healthcare professionals to improve outcomes for anticoagulation management with our INRstar software.

INRstar provides complete decision support for both traditional vitamin K antagonists and the newer oral drugs in over 2,700 locations across the UK.

With the spiraling cost in long-term condition management, we’ve developed a smarter model of self-care –which allows individuals to take more control of their health whilst staying connected to their care team. Our technology joins up data across clinical systems, patient apps and monitoring devices to support a range of conditions including diabetes, asthma, heart disease and COPD.


MAP BioPharma

MAP’s vision is to become the market leader in accelerating patient access to medicines, devices and diagnostics. MAP’s Online service is an up to date, unique, validated, ‘virtual’ expert, which helps you achieve pricing and reimbursement. It builds on our strategic insights and experience of successful consulting projects. To supplement MAP Online, we offer one to one expert advice on a consulting basis, covering market access, health policy and public affairs. 

MAP BioPharma delivers simple, clear process maps, guides and consulting support to the global life sciences industries – including biotech, pharmaceutical, medical device, diagnostics and vaccines.



Indextra’s MedHand Mobile Libraries App has been providing trusted mobile resources for healthcare professionals for more than 15 years, and continues to transform the way healthcare professionals access vital medical expertise and information.

The MedHand Mobile Libraries App offers bespoke institutional subscriptions. The app’s features include complex search, notes, bookmarks, highlights, as well as dictionaries, calculators, adding local content, and offline access after download. 

Indextra also offers a comprehensive subscription app (“Indextra”) for individual healthcare professionals and a custom app development service.

Contact us for more information and sign up for a trial at isabel.rollings@indextra.com or call 07833451595.



Medlior Health Outcomes Research

Medlior Health Outcomes Research Ltd., is a boutique consultancy based out of Western Canada. Medlior offers a variety of research services, including medical writing, systematic reviews, HTA services, and Real World Data (RWD) analytics using Canada’s comprehensive health system data. Driven by scientific expertise and robust methodology, Medlior brings valuable insights to every research project. Medlior will be exhibiting many services relevant to the pharmaceutical industry at the NICE 2018 conference. These services will include our medical writing, systematic reviews and HTA services, but will focus on the utility of Canadian Real World data for industry-sponsored research and HTA submissions.​

Contact us for more information at info@medlior.com or www.medlior.com.



NIHR Innovation Observatory

NIHR Innovation Observatory is a national independent research and horizon scanning centre hosted by Newcastle University. We provide information on innovations to public stakeholders, policy makers and advisory bodies. We track new technologies from patent to patient, providing key information to relevant stakeholders along the innovation pipeline.  NICE is one of our main stakeholders. We have a crucial role in informing them, in a timely manner, about healthcare technologies that might be suitable for consideration within the NICE technology appraisal process. To facilitate this we encourage companies to contact us as early as possible to discuss their plans for the UK.


pH Associates and OAC

OAC and pH offer strategic market access and RWE consultancy.  Our highly qualified 50 strong team provide integrated market access support through expert strategic consultancy and the design and implementation of robust real world evidence programmes.

pH Associates specialise in identifying RWE needs and developing robust RWE plans to support your strategies across the product lifecycle.  Our expanding expert Patient Centred Outcomes Team focusses on delivering the outcomes that really matter to patients.

OAC is a specialist market access agency with unrivalled experience in the delivery of market access programmes from early phase insights to generic/biosimilar strategies.

Rightangled Ltd

Rightangled is a CQC registered healthcare provider for genetic screening and diagnostic procedures.

Our DNA testing service includes an online platform that enables our partner practitioners to provide online medical provision to their patients. Our service has been backed and funded by NHS England and has been specifically designed to enable an easy way for medical practitioner to integrate personalised medicine within their routine practice.